Subsidiary Guarantors Condensed Consolidating Statement of Cash Flows (Details) - USD ($) $ in Millions		9 Months Ended
	Aug. 05, 2016	Sep. 30, 2016	Sep. 30, 2015
Cash flows from operating activities:
Net cash (used in) provided by operating activities		$ 1,697.7	$ 1,356.5
Cash flows from investing activities:
Capital expenditures		(239.5)	(207.3)
Change in restricted cash		(50.5)	25.9
Purchase of marketable securities		(22.8)	(59.1)
Cash paid for Meda's unconditional deferred payment	$ (308.0)	(308.0)	0.0
Proceeds from sale of marketable securities		15.8	29.4
Cash paid for acquisitions, net		(6,151.7)	0.0
Settlement of acquisition-related foreign currency derivatives		(128.6)	0.0
Investments in affiliates		0.0	0.0
Proceeds from Dividends Received		0.0
Loans to affiliates		0.0	0.0
Repayments of loans from affiliates		0.0	0.0
Payments for product rights and other, net		(196.3)	(428.2)
Net cash used in investing activities		(7,081.6)	(639.3)
Cash flows from financing activities:
Payments of financing fees		(95.3)	(114.7)
Change in short-term borrowings, net		48.6	(329.7)
Proceeds from convertible note hedge		0.0	1,970.8
Proceeds from issuance of long-term debt		6,519.8	2,390.0
Payments of long-term debt		(1,067.0)	(4,334.1)
Proceeds from exercise of stock options		11.1	92.8
Taxes paid related to net share settlement of equity awards		(12.9)	(31.7)
Contingent consideration payments		(15.5)	0.0
Capital contribution from affiliates		0.0	0.0
Payments on borrowings from affiliates		0.0	0.0
Proceeds from borrowings from affiliates		0.0	0.0
Investments in and Advances to Affiliates, Dividends or Interest		0.0
Acquisition of noncontrolling interest		(1.0)	(11.7)
Other items, net		1.6	49.6
Net cash provided by (used in) financing activities		5,389.4	(318.7)
Effect on cash of changes in exchange rates		15.1	(37.0)
Net increase in cash and cash equivalents		20.6	361.5
Cash and cash equivalents — beginning of period		1,236.0	225.5
Cash and cash equivalents — end of period		1,256.6	587.0
Non-cash transactions:
Ordinary shares issued for acquisition		1,281.7	6,305.8
Eliminations
Cash flows from operating activities:
Net cash (used in) provided by operating activities		0.0	0.0
Cash flows from investing activities:
Capital expenditures		0.0	0.0
Change in restricted cash		0.0	0.0
Purchase of marketable securities		0.0	0.0
Cash paid for Meda's unconditional deferred payment		0.0
Proceeds from sale of marketable securities		0.0	0.0
Cash paid for acquisitions, net		0.0
Settlement of acquisition-related foreign currency derivatives		0.0
Investments in affiliates		43.6	289.4
Proceeds from Dividends Received		(135.6)
Loans to affiliates		9,115.2	9,946.9
Repayments of loans from affiliates		(8,312.2)	(263.1)
Payments for product rights and other, net		0.0	0.0
Net cash used in investing activities		711.0	9,973.2
Cash flows from financing activities:
Payments of financing fees		0.0	0.0
Change in short-term borrowings, net		0.0	0.0
Proceeds from convertible note hedge			0.0
Proceeds from issuance of long-term debt		0.0	0.0
Payments of long-term debt		0.0	0.0
Proceeds from exercise of stock options		0.0	0.0
Taxes paid related to net share settlement of equity awards		0.0	0.0
Contingent consideration payments		0.0
Capital contribution from affiliates		(43.6)	(289.4)
Payments on borrowings from affiliates		(9,115.2)	263.1
Proceeds from borrowings from affiliates		8,312.2	(9,946.9)
Investments in and Advances to Affiliates, Dividends or Interest		135.6
Acquisition of noncontrolling interest		0.0	0.0
Other items, net		0.0	0.0
Net cash provided by (used in) financing activities		(711.0)	(9,973.2)
Effect on cash of changes in exchange rates		0.0	0.0
Net increase in cash and cash equivalents		0.0	0.0
Cash and cash equivalents — beginning of period		0.0	0.0
Cash and cash equivalents — end of period		0.0	0.0
Non-cash transactions:
Ordinary shares issued for acquisition		0.0	0.0
Mylan N.V. (Parent Guarantor)
Cash flows from operating activities:
Net cash (used in) provided by operating activities		(1.6)	0.0
Cash flows from investing activities:
Capital expenditures		0.0	0.0
Change in restricted cash		0.0	0.0
Purchase of marketable securities		0.0	0.0
Cash paid for Meda's unconditional deferred payment		0.0
Proceeds from sale of marketable securities		0.0	0.0
Cash paid for acquisitions, net		(5,278.5)
Settlement of acquisition-related foreign currency derivatives		(128.6)
Investments in affiliates		0.0	0.0
Proceeds from Dividends Received		135.6
Loans to affiliates		(7,971.9)	(39.5)
Repayments of loans from affiliates		6,838.3	0.0
Payments for product rights and other, net		0.0	0.0
Net cash used in investing activities		(6,405.1)	(39.5)
Cash flows from financing activities:
Payments of financing fees		(95.3)	(89.1)
Change in short-term borrowings, net		0.0	0.0
Proceeds from convertible note hedge			0.0
Proceeds from issuance of long-term debt		6,478.8	0.0
Payments of long-term debt		0.0	0.0
Proceeds from exercise of stock options		11.1	39.5
Taxes paid related to net share settlement of equity awards		(12.9)	0.0
Contingent consideration payments		0.0
Capital contribution from affiliates		0.0	0.0
Payments on borrowings from affiliates		25.0	0.0
Proceeds from borrowings from affiliates		0.0	89.1
Investments in and Advances to Affiliates, Dividends or Interest		0.0
Acquisition of noncontrolling interest		0.0	0.0
Other items, net		0.0	1.3
Net cash provided by (used in) financing activities		6,406.7	40.8
Effect on cash of changes in exchange rates		0.0	0.0
Net increase in cash and cash equivalents		0.0	1.3
Cash and cash equivalents — beginning of period		0.0	0.1
Cash and cash equivalents — end of period		0.0	1.4
Non-cash transactions:
Ordinary shares issued for acquisition		1,281.7	6,305.8
Mylan Inc. (Issuer)
Cash flows from operating activities:
Net cash (used in) provided by operating activities		724.7	(1,417.1)
Cash flows from investing activities:
Capital expenditures		(64.8)	(55.1)
Change in restricted cash		(49.5)	0.0
Purchase of marketable securities		(4.1)	(29.3)
Cash paid for Meda's unconditional deferred payment		0.0
Proceeds from sale of marketable securities		0.0	0.0
Cash paid for acquisitions, net		(931.3)
Settlement of acquisition-related foreign currency derivatives		0.0
Investments in affiliates		(43.6)	(289.4)
Proceeds from Dividends Received		0.0
Loans to affiliates		(417.0)	(4,250.1)
Repayments of loans from affiliates		442.6	240.6
Payments for product rights and other, net		(0.4)	0.0
Net cash used in investing activities		(1,068.1)	(4,383.3)
Cash flows from financing activities:
Payments of financing fees		0.0	(25.6)
Change in short-term borrowings, net		0.0	0.0
Proceeds from convertible note hedge			1,970.8
Proceeds from issuance of long-term debt		0.0	2,390.0
Payments of long-term debt		(500.0)	(4,334.1)
Proceeds from exercise of stock options		0.0	53.3
Taxes paid related to net share settlement of equity awards		0.0	(25.8)
Contingent consideration payments		0.0
Capital contribution from affiliates		0.0	0.0
Payments on borrowings from affiliates		1,380.8	(22.5)
Proceeds from borrowings from affiliates		(1,361.8)	5,696.8
Investments in and Advances to Affiliates, Dividends or Interest		0.0
Acquisition of noncontrolling interest		0.0	0.0
Other items, net		(12.9)	48.3
Net cash provided by (used in) financing activities		(493.9)	5,751.2
Effect on cash of changes in exchange rates		0.0	0.0
Net increase in cash and cash equivalents		(837.3)	(49.2)
Cash and cash equivalents — beginning of period		870.5	112.9
Cash and cash equivalents — end of period		33.2	63.7
Non-cash transactions:
Ordinary shares issued for acquisition		0.0	0.0
Guarantor Subsidiaries
Cash flows from operating activities:
Net cash (used in) provided by operating activities		0.0	0.0
Cash flows from investing activities:
Capital expenditures		0.0	0.0
Change in restricted cash		0.0	0.0
Purchase of marketable securities		0.0	0.0
Cash paid for Meda's unconditional deferred payment		0.0
Proceeds from sale of marketable securities		0.0	0.0
Cash paid for acquisitions, net		0.0
Settlement of acquisition-related foreign currency derivatives		0.0
Investments in affiliates		0.0	0.0
Proceeds from Dividends Received		0.0
Loans to affiliates		0.0	0.0
Repayments of loans from affiliates		0.0	0.0
Payments for product rights and other, net		0.0	0.0
Net cash used in investing activities		0.0	0.0
Cash flows from financing activities:
Payments of financing fees		0.0	0.0
Change in short-term borrowings, net		0.0	0.0
Proceeds from convertible note hedge			0.0
Proceeds from issuance of long-term debt		0.0	0.0
Payments of long-term debt		0.0	0.0
Proceeds from exercise of stock options		0.0	0.0
Taxes paid related to net share settlement of equity awards		0.0	0.0
Contingent consideration payments		0.0
Capital contribution from affiliates		0.0	0.0
Payments on borrowings from affiliates		0.0	0.0
Proceeds from borrowings from affiliates		0.0	0.0
Investments in and Advances to Affiliates, Dividends or Interest		0.0
Acquisition of noncontrolling interest		0.0	0.0
Other items, net		0.0	0.0
Net cash provided by (used in) financing activities		0.0	0.0
Effect on cash of changes in exchange rates		0.0	0.0
Net increase in cash and cash equivalents		0.0	0.0
Cash and cash equivalents — beginning of period		0.0	0.0
Cash and cash equivalents — end of period		0.0	0.0
Non-cash transactions:
Ordinary shares issued for acquisition		0.0	0.0
Non-Guarantor Subsidiaries
Cash flows from operating activities:
Net cash (used in) provided by operating activities		974.6	2,773.6
Cash flows from investing activities:
Capital expenditures		(174.7)	(152.2)
Change in restricted cash		(1.0)	25.9
Purchase of marketable securities		(18.7)	(29.8)
Cash paid for Meda's unconditional deferred payment		(308.0)
Proceeds from sale of marketable securities		15.8	29.4
Cash paid for acquisitions, net		58.1
Settlement of acquisition-related foreign currency derivatives		0.0
Investments in affiliates		0.0	0.0
Proceeds from Dividends Received		0.0
Loans to affiliates		(726.3)	(5,657.3)
Repayments of loans from affiliates		1,031.3	22.5
Payments for product rights and other, net		(195.9)	(428.2)
Net cash used in investing activities		(319.4)	(6,189.7)
Cash flows from financing activities:
Payments of financing fees		0.0	0.0
Change in short-term borrowings, net		48.6	(329.7)
Proceeds from convertible note hedge			0.0
Proceeds from issuance of long-term debt		41.0	0.0
Payments of long-term debt		(567.0)	0.0
Proceeds from exercise of stock options		0.0	0.0
Taxes paid related to net share settlement of equity awards		0.0	(5.9)
Contingent consideration payments		(15.5)
Capital contribution from affiliates		43.6	289.4
Payments on borrowings from affiliates		7,709.4	(240.6)
Proceeds from borrowings from affiliates		(6,950.4)	4,161.0
Investments in and Advances to Affiliates, Dividends or Interest		(135.6)
Acquisition of noncontrolling interest		(1.0)	(11.7)
Other items, net		14.5	0.0
Net cash provided by (used in) financing activities		187.6	3,862.5
Effect on cash of changes in exchange rates		15.1	(37.0)
Net increase in cash and cash equivalents		857.9	409.4
Cash and cash equivalents — beginning of period		365.5	112.5
Cash and cash equivalents — end of period		1,223.4	521.9
Non-cash transactions:
Ordinary shares issued for acquisition		$ 0.0	$ 0.0